Literature DB >> 18591134

Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies.

M G Spillantini1.   

Abstract

Parkinson's disease is neuropathologically defined by the presence of intracytoplasmic Lewy bodies and Lewy neurites. Similar filamentous inclusions are also present in dementia with Lewy bodies, a common late-life dementia, which is clinically similar to Alzheimer's disease. Lewy bodies and Lewy neurites are made of abnormal filamentous material containing alpha-synuclein. Glial cytoplasmic inclusions in multiple system atrophy also contain alpha-synuclein. Using recombinant alpha-synuclein, we have produced synthetic filaments indistinguishable from those present in the intracellular inclusions of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Taken together, these findings indicate that Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies.

Entities:  

Year:  1999        PMID: 18591134     DOI: 10.1016/s1353-8020(99)00031-0

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  35 in total

1.  Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12.

Authors:  Martin Borch Jensen; Vikram Kjøller Bhatia; Christine C Jao; Jakob Ewald Rasmussen; Søren L Pedersen; Knud J Jensen; Ralf Langen; Dimitrios Stamou
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  Synuclein expression in the lizard Anolis carolinensis.

Authors:  Mattia Toni; Carla Cioni; Federica De Angelis; Maria Carmela Bonaccorsi di Patti
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2016-07-08       Impact factor: 1.836

Review 3.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

Review 4.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

Review 5.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

8.  Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy.

Authors:  Selcuk A Tanik; Christine E Schultheiss; Laura A Volpicelli-Daley; Kurt R Brunden; Virginia M Y Lee
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 10.  Therapeutic approaches in Parkinson's disease and related disorders.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.